An affiliate of the Georgia Institute of Technology, the Global Center for Medical Innovation (GCMI) helps verify, validate and accelerate commercialization of new medical technologies that save lives and improve patient care. From our Northyards and 14th Street facilities in midtown Atlanta, we help find the finish line for medtech innovations at any point on the pathway from bench to bedside. Principal investigators, faculty and student projects served include:

Dr. Andres Garcia
Dr. Scott Hollister
Dr. Omer Inan
Coulter Foundation
Over 20 additional GT faculty members

Funding Support for GT Innovators and Researchers with Promising Medical Technologies

Funding varies in specific levels from fiscal year to fiscal year, specifically supports projects with high potential for successful commercialization, follow on funding and improved patient outcomes. Projects are selected by GCMI leadership in consultation with the board of directors. These funds are not for staff / salary or lab support. 

You’re a researcher or engineer who has found a solid unmet clinical need. Excellent! Now the rigorous work begins.

You’re a researcher or engineer who has found a clinician with a strong unmet clinical need your technology might solve.   Outstanding! Too many technologies go looking for problems to solve instead of finding the clinically stated problem first and fitting your technology to meet it in a way that truly works in the clinical…

2022 Fall Capstone Team Wristy Business Tackles a Standard of Care Treatment Suffering from a 40-70% Failure Rate

Treatment for SLL tears relies on casts and orthopedic screws to stabilize bones while a surgically repaired or reconstructed ligament heals. I”Because we followed a solid pathway, we had a lot more latitude to make positive changes that should increase the likelihood of clinical utility and positive patient impact for our device.”

Stars Align – Stridelink quickens march to commercialization with remote monitoring capabilities, CMS CPT codes

The team’s work to date, from concept to the technology’s current state, had primed it to seize the opportunity presented by the January 2022 Centers for Medicare and Medicaid Services (CMS) announcement of five new remote therapeutic monitoring CPT codes.

Early, consistent focus on the unmet need keeps Augment Health on a solid commercialization pathway

“When your ‘north star’ is doing what’s right for the patient and the user, everything else can follow. The best way to accelerate clinical adoption and utility is to prove your early hypotheses, generate data and gather clinical input.”

Phase Zero and Phase One Services Accelerating Wearable Pediatric Stethoscope Path to Commercialization

“I can say with confidence our journey toward commercialization of our new [wearable pediatric stethoscope] medical technology would have taken years longer without GCMI’s Phase Zero and Phase One services.”   As the winner of the 2021 GCMI Baby Sharq Tank competition for their innovative wearable pediatric stethoscope, the interdisciplinary team of Dr. Hong Yeo,…

A Safer Way to Conduct Pericardiocentesis – A Procedure Begging for a Technology to Reduce Mortality

Meet Georgia Tech BME Fall 2021 Capstone Team Five of Hearts   The Unmet Need Heart disease, Viral infections, autoimmune diseases, and cancer can all cause excess fluid to fill the pericardial sac. Physicians frequently perform “pericardiocentesis” by inserting a large 18-gauge needle through the patient’s chest and into the pericardial space to drain this…

What high value preclinical support looks like when re-expressing pacemaking cells for cardiac arrhythmia in pediatrics

“Our confidence in data generated by our in vivo studies with T3 Labs cannot be greater.” – Dr. Hee Cheol Cho   The Preclinical Challenge Dr. Hee Cheol Cho and his team needed sufficient feasibility data from physiologically appropriate preclinical studies to pursue public funding opportunities to complete their translational research for a life changing…

Faculty Researchers and Innovators: What you need to know about IRBs and the medtech innovation process – Insights & Recording

New medical technologies or devices cannot enter stages of research or clinical trials in humans without certain authorizations required by regulatory agencies responsible for safety and efficacy. As far as those regulatory bodies are concerned, the path to clinical trials in humans is the same whether it’s research or commercial driven. Failing to walk that…